Penny Stocks that offer dividends

There are many penny stocks that offer a good dividend yield with capital appreciation. The higher cash levels at companies, including penny stocks, will drive them to increase their dividend yield over the next decade. This combination of higher dividend yield and an economy that recovers will drive up the price of penny stocks over the next decade. Personally, I would rather put my money in growing penny stocks paying a higher dividend yield than a 10-year U.S. treasury bond paying only two percent with limited upside potential and a huge risk of capital losses.

A completely unique market in penny stocks that pays a dividend yield, outside of the banking and resource sector, is Deer Consumer Products, Inc. (NASDAQ/DEER). Deer makes and sells kitchen appliances. A Chinese design firm, it sells its products in China and overseas. This is an interesting play on the burgeoning Chinese domestic economy. Penny stocks that are in this space might offer significant upside capital appreciation, in addition to the dividend yield, if the Chinese domestic market continues to expand.

Deer also makes and sells products under the “Black & Decker” and “Betty Crocker Kitchen” brands, as well as other private label names. I do like it when penny stocks have multiple customers and are not heavily reliant on one big client. This allows some stability when it comes to earnings visibility and the predictability of the dividend yield. If the forward dividend yield is maintained as stated by the company, then the stock should pay out approximately 5.7%. Trading at 0.65 of book value with a 17.56% profit margin, these are decent fundamentals to begin further research in the stock.

Chart courtesy of

The recent earnings release by the company showed that, for the year 2011, net income rose 31%. The company stated that higher prices and increased Chinese sales were a big part of the increase in income. Penny stocks that are increasing their sales and income are a good place to start, even if you are looking for a dividend yield. The stock did move up sharply following the earnings release, but it has since pulled back.

Deer had revenue of $226.7 million in 2011, compared to $175.8 million in 2010, up 29%. The firm had earnings of $39.8 million in 2011 ($1.18 per share), compared to $30.3 million ($0.90 per share) in the previous year. Approximately 68% of sales came from mainland China. The firm stated its expectations for 2012 of earning $1.37-$1.42 per share. The company expects this based off of $270 million to $290 million in revenue.

In a company press release, chairman and CEO Bill He said: “We believe China remains the world’s largest and fastest growing consumer retail market and has strong domestic demand for small household appliances.”

Penny stocks with exposure to China have been hurt recently, no doubt about it. Even firms that pay a good dividend yield, such as Deer, have been hurt. If we are to believe the CEO of the firm, there was no word of a decrease or suspension in the dividend yield. Obviously, no one can read minds or predict the future, and investing in penny stocks deals a lot with the trust in management.

I usually like investing in penny stocks with some momentum, as other investors signal their intentions in penny stocks with their money. If they like penny stocks, they buy them, and the price starts to form a base from which it moves up. Penny stocks continuing to decline does raise some worry, but if the fundamental results come in as the CEO states, then perhaps this might be a long-term stock worth looking further into. While I’m not advocating buying shares right now, I certainly would keep my eye on this stock.

Share This:

Canopy Growth Corp (CVE:CGC)

Canopy Growth Is a Solid Marijuana Stock

Marijuana stocks are likely to outperform this year, buoyed by seven U.S. states that have already legalized marijuana, while the other 10 states will discuss pot change in 2017. In addition, the Canadian authorities could authorize weed this year, as black market is estimated around $7 billion. Future fundamentals for marijuana stock also appears strong, thanks to the potential growth in legal marijuana demand.
Marijuana sales are likely to increase by 178% to $20.6 billion by 2020, with a compound yearly development rate of 29%.
Canopy Growth Corp (CVE:CGC) is a diversified company, operating through its subsidiaries, including Tweed Inc., Tweed Farms Inc., and Bedrocan Canada Inc. The company has strong penetration in Canadian markets. It supplies pot to half of Canada’s present therapeutic cannabis base following the acquisition of Mettrum Ltd. The Canadian medicinal cannabis industry pulled in $869.0 million in lawful deals in 2016.
With the keen interest of Canadian Prime Minister, legal marijuana sales are anticipated to stand around $22.6 billion in the coming years. To place that into viewpoint, Canopy Growth is set to capitalize on growth opportunities.
This year, it altered its stock ticker to WEED, and continues to trade on the TSX. The company has a market capitalization almost $1.0 billion. Its revenue in the latest quarter increased 245% over the same period last year, while its revenue enlarged 22% sequentially to $8.5 million. It sold over one metric ton of marijuana in the latest quarter.
Moreover, the company has the potential to turn a strong revenue growth into big profits. Its net income was standing around $5.4 million, relative to earnings of $3.9 million over the prior year period. It also appears in a strong cash position to invest in growth opportunities, thanks to cash in hand of $45.5 million at the end of most recent quarter.

Share This:

Picking a penny stocks newsletter

You probably already know that there are a LOT of penny stock newsletters out there. Once you start comparing them is likely to leave your head spinning. The irony of this situation is that we want choices but not too many choices. Ideally we should be able to limit our choices to 2-3 and then pick one.

Now, how do we start filtering ALL of those newsletters. Start by making a list of things that you are looking for. The following is a good place to begin:

1) Education

It’s important to look for newsletters that offer access to training or learning resources about penny stock investing and/or investing in general. Investing is an art and a science. The fundamentals remain the same but you always find something new to learn. Ideally the newsletter that you choose should cater to all the levels of investing. Some publishers work best for intermediate or advanced investors while others are best for newbies. Keeping in mind what your knowledge level is choose the right subscription for your needs.

2) Support

Some investors need a lot of support while others don’t need to much. Once again, it’s important to know your own approach. Its almost always nicer to have access to some sort of forum or bulletin board where you can share ideas and strategies with other subscribers. This is important because you get a chance to interact with and grow with other members. When you get more experienced you will have a chance to share with the other newer folks in the forum. That’s when true learning happens – by teaching.

3) Picks

This is understandably the most important reason to subscribe to any penny stock newsletter. Obviously, you want some good or great microcap stock picks. You want a newsletter that more winners than losers (100% success rate doesn’t exist). Pay close attention to a newsletter’s win/loss ratio. Usually newsletters will let you preview their sample newsletters or get alerts via email. Subscribe to a couple of these alerts and paper trade those penny stocks. You will be able to see fairly quickly whether the newsletter is worth it or not.

4) Money-back Guarantee or Free Trial

Look for some sort of money-back guarantee. No newsletter can guarantee you returns. If they do, then run in the opposite direction. But, the better newsletters will offer you some sort of money-back guarantee or a free trial. Read the fine print and don’t commit to any funny payment plans unless you are sure.

5) Check The Disclosures

Some newsletters are compensated by companies or other related entities for recommending them to their subscribers. In simplest terms if penny stock newsletter A recommends stock XYZ, sometimes its because XYZ or some other company affiliated with XYZ has paid them to recommend that stock. Newsletters will make this disclosure in the extensive fine print. Read it carefully. We recommend staying away from such recommendations unless you have done your own unbiased research.

Phew! That was a lot of great advice. Now, you should be able to choose the ideal microcap stock newsletter quickly. Ready to start your journey into profitable penny stock trading?

Share This:

Medizone International, Inc. (OTCBB: MZEI)

Medizone International, Inc. (OTCBB:  MZEI)

is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure.

To meet the unique challenges of hospital acquired infections, Medizone has assembled an international team of professional engineers who are finalizing design of the first pre-manufacturing prototype to be used in hospital beta testing, which will commence later this spring.

Given the outstanding range of bactericidal kill rates achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse applications.  While the acute demand of hospital acquired infections remain pre-eminent the need for bio-terrorism applications grows each day.

Commercial Viability ofAsepticSure™ Hospital Sterilization System

From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

AsepticSure™ BioTerrorism Applications

A field hardened version of AsepticSure™  is anticipated to be used in bioterrorism settings internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and has the potential to save lives.  The potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications.

Unprecedented Kill Rates Foundation for Second Patent Application and Full Scale Hospital Mockup Underway

The successful completion of the first full round of room scale testing with AsepticSure™ sterilization system indicated all pathogens of cause with HAIs were completely eliminated from stainless steel surfaces at concentrations well above 6 log. These results have confirmed the laboratory findings reported earlier this year, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment.

Work will continue on the room scale testing program in order to expand understanding of factors that will enhance the efficiency and effectiveness of AsepticSure™, particularly when dealing with contaminated textiles in time sensitive hospital spaces.  The start of beta testing is anticipated to begin the fourth week of August.

Four Instrumented Prototypes

Medizone will build four highly instrumented prototype units for use in its hospital program, thereby enabling precise performance assessment of all AsepticSure™ systems as concurrent outcome measures, which will form the basis for final production design work, manufacturing and ultimately commercialization later this year.Medizone International announced unprecedented success in being able to predictably achieve 6 log (99.9999%) kill rates for the causative agents of Hospital Acquired Infections (HAIs) represented with AsepticSure™.

All samples tested during the third round of trials were either completely destroyed, that is no growth compared to the control samples, or so significantly reduced that the effect met the 6 log definition for sterilization.

The actual results of this series of tests indicate reductions in pathogens, commonly associated with HAIs, can reliably be achieved by AsepticSure™ as follows:

  • >6.5 log for C difficile
  • >7 log for MRSA
  • 7 log for E-coli
  • 6.6 log for VRE
  • 7 log for Pseudomonas aeruginous
  • > 7 log for Bacillus subtilis

The sterilization of contaminated hospital spaces with a fully portable unit is now within reach without enormous expense, which will translate into greatly reduced suffering, thousands of lives saved and a dramatic cost benefit for the health care system globally.

Full Scale Hospital Mock Up Underway

Medizone’s research has now progressed to the full-scale mock up.  By introducing the same combinations and protocols to room scale testing that produced >6 log with all HAI pathogens in the laboratory, our research team is confident the results produced should coincide with what has already been achieved in the most recent round of laboratory trials.  Initial results from these scale-up trials can be expected in the near future.

AsepticSure™ Hospital Sterilization System

In parallel research conducted at BioZone Corporation, Medizone’s engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.

Commercial Viability ofAsepticSure™ Hospital Sterilization System

From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

Second Patent Application for Both AsepticSure Hospital Version and Government Variant

On July 7th, the Patent Cooperation Treaty (PCT) filing was announced. The significance of that filing should not be underestimated. It represents the international cornerstone of intellectual property protection for AsepticSure™. In subsequent discussions with our lead patent attorney, additional filings have been suggested in order to build a very strong “patent fence” around our initial PCT application. The first of those filings may be anticipated later this year.

On January 20, 2010, Medizone International, Inc. filed a second patent application was filed in combination with its previous patent application for AsepticSure™ filed in July of 2009. This patent application affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.

The integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative motivated this filing.

AsepticSure™ Hospital Sterilization System

In parallel research conducted at BioZone Corporation, Medizone’s engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.

Medizone International, Inc. Research Laboratory

Medizone has a  BSL2A Certified Laboratory  is Located in Innovation Park, Queen’s University at Kingston, Ontario, Canada

This laboratory is fully equipped to meet bio-safety level 2 laboratory standards and is dedicated exclusively to Medizone research.

The laboratory is located in the heart of one of the finest bio-medical communities and is providing a primary research and development platform for the Corporation as it proceeds down what is now a clear path to commercialization with its lead product, AsepticSure™.

Given the outstanding range of bactericidal kill rates achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications.

This facility provides Medizone International a platform for laboratory research which has the potential to expand beyond AsepticSure™.

Virtually Unlimited Demand for Product

The United States Congress and various State Legislatures have taken official notice of the issues associated with Hospital Acquired Infections.

Laws are being in enacted in a majority of States to require that hospitals report the number of Hospital Acquired Infections.

Medicare will NO LONGER REIMBURSE HOSPITALS for treating hospital acquired infections.  In essence their point is simple:  You made them sick.  You make them well.  Private insurance carriers are beginning to do the same.

Hospitals are being forced to COME OUT OF THE CLOSET with their facts regarding hospital acquired infections.

Demand for an effective product is huge.

The Silent Epidemic

The chart above represents the Hospital Acquired Infections and Deaths for U.S. hospitals in 2002 based on the most recent CDC Report which tabulated these figures.

As the notes that came from the source for this chart point out, Hospital Acquired Infections are a huge problem in hospitals today.  Although this data is from 2002, the situation has progressively become more serious.  See:  CDC Public Health Report at page 163 of the Report.   Here are the notes that accompanied the chart found on page 163 of the report:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

Hospital Acquired Infections in the United States

In 2002, there were approximately 1.7 million total infections.

Of these:

  • 33,269 occurred among newborns in high-risk nurseries
  • 19,059 among newborns in well-baby nurseries
  • 417,946 among adults and children in ICUs
  • 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987.

Of these:

  • 35,967 were for pneumonia
  • 30,665 for bloodstream infections
  • 13,088 for urinary tract infections
  • 8,205 for surgical site infections, and
  • 11,062 for infections of other sites.[1]

Hospital Acquired Infections Are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

Hospital Acquired Infections

  • C-difficile
  • E-coli
  • Pseudomonas aeruginous
  • MRSA
  • VRE

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.


Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

Current Methods at Sterilization Are Not Sufficiently Effective

Medizone Leadership:

Edwin G. Marshall – Chairman of the Board & Chief Executive Officer

Following a period of time in which he unsuccessfully attempted to influence and guide former management as a shareholder, a successful hostile proxy action was completed on June 12,1997.

Mr. Marshall took over as Chairman of the Board. Milton G. Adair, former President and CEO of Gull Laboratories was appointed Chief Executive Officer and President. Mr. Adair left the Company to pursue other interests in 1998. Mr. Marshall then took over the additional responsibility of Chief Executive Officer.

Mr. Marshall attended Santa Rosa Community College and the College of Marin, studying fire science and business administration. Until 1978 Mr. Marshall worked in the fire service in a city with a major chemical industrial complex, leaving with the rank of Captain. A successful private investor since 1973 in precious metals, securities and real estate, after leaving the fire service he went to work in the real estate brokerage business. From 1978 until 1995 he pursued various business interests in real estate brokerage, a vacuum forming business in the plastics industry, an industrial computer controls company, and an automobile and truck dealership. Since 1997 he has devoted all of his business time to management responsibilities with Medizone.

Richard Garret Solomon – Director and Executive Officer

Mr. Solomon first invested in Medizone in 1992. In 1995, Medizone New Zealand Limited (a partially owned subsidiary of Medizone International) was formed as a 50/50 joint venture. In January 1996, until February 1997, Mr. Solomon was a Director of Medizone International, Inc. and has rejoined the board as of May 1, 2000.

Mr. Solomon received a Bachelor of Commerce (University of Otago), Diploma of Business and Industrial Administration (University of Auckland), and is an Associate Chartered Accountant. His career has been in business and investment, and for 20 years he developed and ran his own private hospital operating company, Haven Care Hospitals Limited. He was a longstanding Board member and President of the New Zealand Hospitals Association. He lead the establishment of The New Zealand Council of Healthcare Standards, Inc.

Daniel D. Hoyt – Board Member

Mr. Hoyt graduated from Indiana University with a Bachelor of Science degree in General Business Administration in 1962. For the past 31 years, he has been involved in the life insurance and group benefits industry achieving both industry-wide and national company recognition for production and mentorship. Mr. Hoyt takes great pride in the relationships he has built through consultations with his business clients that range from large public companies to small private businesses. Throughout his career, he has served as mentor to many other entrepreneurs. Mr. Hoyt previously worked 7 years as an account executive at Merrill Lynch and as Chief Executive of two and Vice President of one Chamber of Commerce in Indiana. In addition to his board position with Medizone International, Mr. Hoyt is the Chairman of the Board of Biological Systems, Inc., a bio-cleansing, microbial remediation system dealing with natural animal fats and oil-based materials.

Mr. Hoyt is and has been very active in his community and church. These activities and positions include: current board member of the Indiana University Cancer Center Development Board; former board member and chair of Saint Mary of the Woods College, Terre Haute, IN; board chair of Our Lady of Fatima Retreat Center; twice chair of the Parents Association of Ball State University. Numerous other board and leadership positions include St. Elizabeth Home for Unwed Mothers, past president of Indianapolis Sierra Club, Prevent Blindness of Indiana; Indianapolis Business Development Foundation and Christamore Settlement House. He is currently chair of the Rebuild My Church Board of Visitors of Marian College, an active member of Immaculate Heart of Mary Catholic Church and a founding member of Pink Ribbon Connection, a newly formed group serving the needs of breast cancer patients and survivors in central Indiana (he is a 10-year survivor).

Steve M. Hanni – Chief Financial Officer

Mr. Hanni has served as Medizone International’s Chief Financial Officer since April 2, 2002.

Additionally, Mr. Hanni is the Audit Partner-in-Charge and Vice-President of the accounting firm, Stayner, Bates & Jensen, P.C., located in Salt Lake City, Utah. He was formerly a partner with the accounting firm, HJ & Associates, LLC, also located in Salt Lake City. HJ & Associates serves as the Company’s audit firm.

Mr. Hanni has worked closely with many different types of companies and organizations and has extensive auditing and consulting experience in the following industries: Mortgage Banking, Construction, Manufacturing, Oil and Gas companies, Retail, High Technology, Non-profit and Pension Plans.

In addition, Mr. Hanni has significant experience with Securities and Exchange Commission listed companies, including registration statements, public offerings and audits as well as providing management advisory services.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)

(See Medizone International Video)

Telephone:  415-868-0300
Fax:  415-868-2344
Post Office Box 742
Stinson Beach, CA 94970

This Profile contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 550,000 144 restricted common shars by the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We hold 100,000 shares of restricted 144 stock and have not registered the shares. We have taken no free trading shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program or for a significant period of time afterward. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold only restricted shares and will not register or sell these shares at anytime during the promotional period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Pentony Enterprises: [email protected] Direct: 469.252.3031, 1601 Berwick Drive, McKinney,

Share This:

Level II Software Investing Tools Archive G


Level II Software Investing Tools Will Change The Way You Trade


Using Stock Market Level II Data To Time Your Penny Stock Trade

Level II Software Investing tools use NASDAQ Level 2 Quotes to time entry and exit points for your trades.

How Does Level II Data Help Me Trade?

Basically, Level 1 data tells you the best Bid and Ask price of a given stock, and includes the current price per share, and volume traded. This information is fine for a snapshot of where your stock is currently trading.

But to effectively judge the direction a stock price may be moving, NASDAQ Level 2 Quotes are necessary. Level II software investing tools study the Bid and Ask prices in-depth. That is, using Level 2 data, you are able to see the market makers and their order sizes beyond the Level 1 picture.

By the way, I am not compensated by Bloomfield Investment Club in any way. but, they seem to offer a good Level II package at a fair price.

For example, NITE may be the best inside Ask for a stock with a size of 5,000 and price of .05, while just above it is ARCA with an Ask size of 10,000 and price of .06.

Over on the Bid side, HDSN may be trying to buy 50,000 shares at a price of .045, and beneath that, DOMS may have a Bid in for 50,000 shares at .04.

Level II software investing programs would look at this Bid/Ask structure and determine that Bid support is huge compared to an apparent thin wall on the Ask. Given this, the stock trade software may signal a buy order.

Keep in mind that “size” does not always translate to an exact number of shares. In the penny market, NASDAQ Level 2 Quotes sizes tend to max out the size system. A quoted size of 5,000, may actually represent 500,000, or even 1 million.

Black Box Warning

Like any stock trade system, Level II software investing systems depend on trends and previous stock price behavior based on historical data. As traders, we all know that past performance does not guarantee future results. So, while the software may give you a buy signal, you still need to use your judgment, based on current events and your research, to determine your entry and exit points.

There are numerous places to obtain NASDAQ Level 2 Quotes, but you’ll have to pay for the access to real time data feeds. If you are happy with a 20 minute delay in your data, and want to test drive Level 2 Quotes.

In my opinion, delayed quotes are fine for casual trading. But to effectively use day trading, swing trading, or momentum trading strategies, you need real time quotes.

Where To Find Level II Software Investing Tools

Here are the links to several companies that may be able to help you out. I am not affiliated with any of these, and merely list them as a convenience for you. You could also conduct a search to find more alternatives.

The services these companies offer is above and beyond basic NASDAQ Level 2 Quotes services. Also, important note: if you plan to trade the penny markets, make sure their quote or trade alert service covers the OTCBB and Penny Stocks markets. Many do not.

Share This:

Three Penny Stocks to Watch archive f

Three Penny Stocks to Watch in the Second Half

Penny Stocks is a perfect way of starting trade for new investors who are seeking to expand their hard earned money while staying on the safer side amid their low price per share. Penny stocks usually trade under $1 per share but some analysts consider all those stocks as penny stocks that are trading under $5 per share. Unlike large-caps that have significantly higher per share prices, penny stocks do not require large capital.

Nevertheless, investing in penny stocks and making profits from your trades require some investing experience and keen eye on the global business activities. Irresponsible risk management could result in big losses in a very shorter period of time. Once you took a position in any company with bleak future fundamentals and low liquidity position, the chance of losing money are greater than generating profits from that trade.

On the other hand, when you used the right strategy and timing of investing in any particular penny stock, the chance for wining are higher. It is also equally important for new investors and beginners to predict the exit point for penny stocks to comfortably capitalize on recent gains. Below, I’ll take a look at few penny stocks that have strong upside potential in the coming days and have had posted significant profits in the last couple of quarters.

Golden Minerals Co. (AUMN) engages in the mining of silver and gold bars, lead, precipitates zinc, and pyrite concentrates. The company’s market capitalization is standing around 74.34 million and its trading volume is around 919,125 shares.

Mining companies are always cyclical in nature and they have offer a lot of room for traders to make profits. Share price movement and financial performance of mining penny stocks are directly correlated with the commodity prices. If investor has some hold on precious metals and commodities, they can easily make profits from its investments in mining stock.

Golden Minerals share price soared nearly 365% since the start of this year, a significant price appreciation for any company and its share holders. This clearly means that if someone had invested in Golden Minerals at the beginning of this year, their initial investment have increased 365%. Falling crude oil prices, volatility in the stock market, stable interest rates and supply and demand dynamics are key drivers for significant price rally. New traders always need to look at these drivers if they are planning to invest in mining related stocks.

Despite the significant share price rally, Golden Minerals share price have further upside potential moving forward. Crude oil prices are unlikely to rebound in the near-term and global economic environment is expected to remain week, which could move investors towards safe heaven assets and mining stocks. Therefore, Keep Golden minerals at your watch list.

Sirius XM Holdings (SIRI) is among those penny stocks that have generated significant revenue and earnings growth in the last couple of years on the back of its innovative strategies. It provides satellite radio broadcasting services including free music, news and comedy, premier sports, entertainment and key events and wide range of other programs.

Five years back, Sirius XM was only trading around 1.50 per share. This penny stock surged nearly 125% in the last five years and nearly going to become a small cap-stock. Some penny stocks with strong business fundamentals have potential to turn their status as a small-cap stock from a penny stock.

The company’s future fundamentals are strong as the company has recently beaten analyst estimated for both earnings and revenue for the second quarter of this year. Its revenues surged nearly 10%, while EBITDA increased almost 13% compared with the same period of last year. With the growth in earnings, its cash generating potential has also been expanding year over year. Therefore, buying and keeping this penny stock on the watch list could result in healthy gains.

Plug Power, Inc. (PLUG) offers alternative energy technology, particularly focusing on the design and development of fuel cell systems for the industrial off-road market. Plug Powers share price declined in the last few months amid slow off-road market. However, this penny stock is presenting a perfect case of buying low and selling high. Its stock price is currently trading around $1.71 per share, significantly lower from 52-week high of 2.52 per share.

The company’s future fundamentals are strong and its share price has significant upside potential. Recently, the company has beaten analysts earnings estimate by 0.02 per share for the second quarter of this year. In addition, the company’s revenue of 37.9 million increased 59% compared with the same period of last year. New investors must add this penny stock on their watch list, as this company has substantial upside potential considering its revenue and earnings growth.


New investors can make big profits by investing in penny stocks by using timely and right strategies. If investors want to make profits from its trades, they need to have a keen eye on the company’s future performance and business fundamentals. Those penny stocks that have strong business models and potential to generate a sustainable growth should be on new investors watch list.


Share This:

buying penny stocks archive c-e

There are other names for a penny stock: a micro cap stock or a nano stock. How does an investor buy penny stocks, what is the procedure that one can follow in order to invest in penny stocks? These are the 2 most frequent questions asked by investors who want to start trading.

Recommendations on the various websites by traders and agents, who are engaged in doing research of the companies offering penny stocks is a must read. At least the information is available, how far it is true and applicable to your needs is your decision.

Try out the various investing methods available on the internet. It is meant for beginners and shows you step by step how to make decisions on trading. Newsletters are available and some websites of traders offer a membership with a fee, to which you can subscribe. After all you need to invest some money too to get massive returns.

When you are buying penny stocks for the first time, start low, start with only about 10% of your money. You can buy penny stocks online on some brokerage sites or you can divert your funds through a stock broker, who will naturally advise you what to buy, when to buy, how much to buy and when to sell. Penny stocks are traded in the over-the counter-market. There is a middle-man or a broker who trades the stock representing the investor. A transaction is arranged between the investor and a third party, and the broker then encashes the commission for his brokerage. The trick is to learn when to sell the stocks and for each company the gains and the losses each day are different, so there is no set formula for selling them. Some penny stock exchanges guarantee no loss, but again that is for you to check and risk for yourself.

Very often the broker does not charge a commission, but he makes money on each transaction by buying and selling stocks at the correct time. This is known as the ‘spread’. It is a term used in the penny stock market meaning the difference between the bid and the ask price. This can be anything between 30-100%, and the broker profits from the spread because he may have risked holding the penny account himself and then sold it at an advantageous time. So the risk of the investor also rises, that is why one has to be very careful about choosing a good broker, because there are many frauds in the market. The buying and selling of penny stocks is not simple and there is a lot of money involved too, but most small companies still have them to generate funds, especially if they are new.

So which are the best type of penny stocks to buy?  We took some votes and asked 1,000 penny stock traders which they preferred. Here were the results.

Marijuana stocks       received   420 votes ironically

Oil Stocks    received   230 votes

Biotech Stocks      received  120 votes

Gold Stocks   received 110 votes

Alter Energy Stock   received   90  votes

Food and Beverage Stocks   received  50 votes


Share This:

Penny stock Archive A-B

We all want to find hot penny stocks and investment that can turn our $.10 per share and $1 per share, with 100,000 shares, or whatever your actual numbers might be. But let’s face it, it’s not that easy to pick these. Some say there’s a better chance of profiting picking off the dart board than all the educated speculations. Others are more optimistic, and swear by software aided selection systems or obscure government filings to tip off some potential changes in the company.
If you are open minded, and are willing to study and research a investment strategy, I believe you can get the feel of how to do it, and consistently make the right moves versus the wrong moves. A big part of investing successfully is to not let your emotions get in the way, and to go with preset disciplines and principles.
I too, am weary of over-hyped promises out there for this system or that system, but at the end of the day, they all can provide some value. You simply have to find a investing system that your personality/emotions can handle, an one that works when you do it with good discipline.
For example, a super effective penny stock trading system that is fast paced and keeps you on the edge of your seats for the entire day, may not be the style for you if you are not into that adrenaline rush. As a matter of fact, you might make tons of mistakes you may never recover from.
On the other hand, a long-term, sure-bet investment that may take a year to profit may not be right for you, because your preference is fast paced, in and out investing style. You get the picture.
To find the best style or system for yourself, simply try out a few systems, and actually test them out during the trial period, and once you get the hang of them and pick one you like, return the ones you don’t like as most legitimate systems offer some kind of money back guarantee, so you can’t lose. Good luck and I hope to see you on the other side!

Another thing to take a look at is what type of penny stocks are currently hot. For the last couple years Marijuana stocks have been very hot.  There were also times when Gold stock and Oil stock was very popular.  Biotech stocks usually get popular during winter months. So always be ready to spot trends.

Share This:

VPCO – Vapor Corp. what are the insiders saying?

What Insiders Say About Vapor Corp

Vapor Corp. (OTC:VPCO) stock is currently trading at about $0.00 and lots of rating firms seem to have a target price set on the stock. The median 12-month price target of 1 analysts covering the company is $6.00, which suggests the stock could still gain more than 100 percent.

The highest analyst price target is $6.00, which implies a gain of 100 percent. And roundups of analyst notes show that 0 are rating the stock a buy while 0 rate VPCO a strong buy. There are 0 equity research firms suggesting a Hold and 0 consider it Sell.

Several executives took part in recent insider activity for the stock. Its 10% Owner MARXE AUSTIN W & GREENHOUSE DA sold 50,000 company shares for $288000, in a transaction on 2014-02-14. Following the transaction, the 10% Owner is left with a stake of 288 shares, currently valued at $0. Meanwhile, Dir of Issuer sole opertng sub Galazan Isaac purchased 0 shares worth $51000.5, through a transaction dated 2013-10-29.

Following the completion of the transaction, the insider is left with a stake of 0 shares, amounting $0. VPCO CFO Press Harlan also purchased 0 shares, at a stock price of $9799804. This transaction occurred on 2013-10-29 totals $159000.46. After this transaction, the insider’s stake stands at 0 shares, with a market value of $0
Insiders own 32.04 percent of the stock. Doron Ziv is one of the largest insider shareholders in Vapor Corp. (OTC:VPCO) , according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 7,514,604 shares which have current market value of around $0.Jeffrey Elliot Holman is another major inside shareholder in the company. The insider owns 5,805,548 shares as of 2073.41%, currently worth $0. Isaac Galazan is ranked as third insider holder of the stock. This insider holds 846,302 shares with a market value around $0 as of recent close.

Share This:

STEV – Stevia Corp is Looking Strong

Stevia Corp is Looking Strong

Stevia Corp (OTCMKTS:STEV) is exchanging lower in late sessions on developing volume. STEV is a stock with a background marked by huge moves running from well under a dime to $0.339 highs this time a year ago.

On April 20 STEV reported natural chemist and previous MD Anderson Cancer Researcher Dennis Hill has acknowledged a position on Stevia Corp’s. recently framed Advisory Panel. Dennis Hill has separated himself as being one of only a handful few individuals on record on the planet that accomplished finish reduction of growth exclusively using cannabis without traditional tumor treatment, for example, radiation or chemotherapy.

Stevia Corp (OTCMKTS:STEV) is a ranch administration organization and medicinal services organization concentrated on growing very dietary, high esteem items through exclusive plant reproducing, astounding rural approachs and inventive post-reap strategies.
STEV works various divisions in stevia and mechanical hemp and just achieved benefit as indicated by their keep going 10Q documented on November 19.

The energy on stevia is obvious and numerous foresee it is bound to end up the primary road workhorse characteristic high strength sweetener available. Stevia is a sweetener and sugar substitute separated from the leaves of the plant species Stevia rebaudiana.

The dynamic mixes of stevia are steviol glycosides, which have up to 150 times the sweetness of sugar is warmth stable, pH-stable, and not fermentable. These steviosides negligibly affect blood glucose, which makes stevia alluring to individuals on sugar controlled weight control plans. Stevia’s taste has a slower onset and longer span than that of sugar, and some of its concentrates may have a biting or licorice-like delayed flavor impression at high fixations.

STEV President George Blankenbaker who has lived in Asia for a considerable length of time initiated the Company’s advancement of high Reb-A Stevia cultivating in Vietnam and in addition secured essential circulation through PureCircle, the industry’s driving stevia refiner.

Share This: